{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T22:59:34Z","timestamp":1785365974074,"version":"3.55.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100018537","name":"National Science and Technology Major Project","doi-asserted-by":"publisher","award":["2018ZX10722301-003"],"award-info":[{"award-number":["2018ZX10722301-003"]}],"id":[{"id":"10.13039\/501100018537","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82102406"],"award-info":[{"award-number":["82102406"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["GWVI-11.2-YQ03"],"award-info":[{"award-number":["GWVI-11.2-YQ03"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"publisher","award":["HS2021SHZX001"],"award-info":[{"award-number":["HS2021SHZX001"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014137","name":"Shanghai Shenkang Hospital Development Center","doi-asserted-by":"publisher","award":["SHDC2020CR1011B"],"award-info":[{"award-number":["SHDC2020CR1011B"]}],"id":[{"id":"10.13039\/501100014137","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.cmi.2025.11.015","type":"journal-article","created":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T17:05:23Z","timestamp":1764003923000},"page":"429-439","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["A 6- to 9-months oral regimen for rifampicin-resistant tuberculosis: a randomized open-label noninferiority trial in China"],"prefix":"10.1016","volume":"32","author":[{"given":"Feng","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yilin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cui","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hengzhong","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianhong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongying","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanbo","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jichan","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yungui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingying","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiming","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zebao","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiqing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yena","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinlan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianfeng","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yajiao","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolin","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanlin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2025.11.015_bib1","series-title":"Global tuberculosis report 2024","year":"2024"},{"key":"10.1016\/j.cmi.2025.11.015_bib2","series-title":"WHO consolidated guidelines on tuberculosis: Module 4: Treatment and care","year":"2025"},{"key":"10.1016\/j.cmi.2025.11.015_bib3","series-title":"WHO consolidated guidelines on tuberculosis: Module 4: Treatment: Drug-resistant tuberculosis treatment. 2022 update ed","year":"2022"},{"key":"10.1016\/j.cmi.2025.11.015_bib4","series-title":"Key updates to the treatment of drug-resistant tuberculosis: Rapid communication, June 2024","year":"2024"},{"key":"10.1016\/j.cmi.2025.11.015_bib5","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/S1473-3099(21)00470-9","article-title":"Assessment of epidemiological and genetic characteristics and clinical outcomes of resistance to bedaquiline in patients treated for rifampicin-resistant tuberculosis: A cross-sectional and longitudinal study","volume":"22","author":"Ismail","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2025.11.015_bib6","series-title":"WHO treatment guidelines for drug-resistant tuberculosis. 2016 update","year":"2016"},{"key":"10.1016\/j.cmi.2025.11.015_bib7","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/s12879-021-05870-w","article-title":"Refining MDR-TB treatment regimens for ultra short therapy (TB-TRUST): Study protocol for a randomized controlled trial","volume":"21","author":"Weng","year":"2021","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.cmi.2025.11.015_bib8","series-title":"WHO consolidated guidelines on tuberculosis: Module 4: Treatment: drug-resistant tuberculosis treatment","year":"2020"},{"key":"10.1016\/j.cmi.2025.11.015_bib9","series-title":"Common terminology criteria for adverse events (CTCAE)","year":"2017"},{"key":"10.1016\/j.cmi.2025.11.015_bib10","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa1811867","article-title":"A trial of a shorter regimen for rifampin-resistant tuberculosis","volume":"380","author":"Nunn","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cmi.2025.11.015_bib11","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01770-2018","article-title":"Introducing molecular testing of pyrazinamide susceptibility improves multidrug-resistant tuberculosis treatment outcomes: A prospective cohort study","volume":"53","author":"Sun","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1016\/j.cmi.2025.11.015_bib12","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1183\/23120541.00537-2020","article-title":"Outcomes with a shorter multidrugresistant tuberculosis regimen from Karakalpakstan, Uzbekistan","volume":"7","author":"du Cros","year":"2021","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.cmi.2025.11.015_bib13","article-title":"Outcomes of a nine-month regimen for rifampicin-resistant tuberculosis up to 24 months after treatment completion in nine African countries","volume":"20","author":"Schwaebel","year":"2020","journal-title":"Eclinicalmedicine"},{"key":"10.1016\/j.cmi.2025.11.015_bib14","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1016\/S0140-6736(22)01883-9","volume":"400","author":"Mok","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2025.11.015_bib15","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa2119430","article-title":"Bedaquiline-pretomanid-linezolid regimens for drug-resistant tuberculosis","volume":"387","author":"Conradie","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cmi.2025.11.015_bib16","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S2213-2600(23)00389-2","article-title":"Short oral regimens for pulmonary rifampicin-resistant tuberculosis (TB-PRACTECAL): An open-label, randomised, controlled, phase 2B-3, multi-arm, multicentre, non-inferiority trial","volume":"12","author":"Nyang'wa","year":"2024","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.cmi.2025.11.015_bib17","article-title":"Effects of bedaquiline combined with fluoroquinolone and\/or clofazimine on QT interval in patients with multidrug-resistant tuberculosis: A retrospective study","volume":"11","author":"Li","year":"2023","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.cmi.2025.11.015_bib18","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01448-22","article-title":"QT interval prolongation with one or more QT-prolonging agents used as part of a multidrug regimen for rifampicin-resistant tuberculosis treatment: Findings from two pediatric studies","volume":"67","author":"Ali","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2025.11.015_bib19","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1093\/jac\/dkac019","article-title":"Linezolid toxicity in patients with drug-resistant tuberculosis: A prospective cohort study","volume":"77","author":"Wasserman","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2025.11.015_bib20","doi-asserted-by":"crossref","first-page":"ofac500","DOI":"10.1093\/ofid\/ofac500","article-title":"Low-dose linezolid for treatment of patients with multidrug-resistant tuberculosis","volume":"9","author":"Mase","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.cmi.2025.11.015_bib21","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1056\/NEJMoa2117166","article-title":"A 24-week, all-oral regimen for rifampin-resistant tuberculosis","volume":"387","author":"Nyang'wa","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cmi.2025.11.015_bib22","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1016\/S0140-6736(22)02078-5","article-title":"Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): An open-label, multicentre, randomised, non-inferiority trial","volume":"400","author":"Goodall","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2025.11.015_bib23","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.03300-2020","article-title":"World Health Organization recommendations on the treatment of drug-resistant tuberculosis, 2020 update","volume":"57","author":"Mirzayev","year":"2021","journal-title":"Eur Respir J"},{"key":"10.1016\/j.cmi.2025.11.015_bib24","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.cmi.2020.06.004","article-title":"Early outcome and safety of bedaquiline-containing regimens for treatment of MDR- and XDR-TB in China: A multicentre study","volume":"27","author":"Gao","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2025.11.015_bib25","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/S1473-3099(21)00811-2","article-title":"Treatment outcomes 24 months after initiating short, all-oral bedaquiline-containing or injectable-containing rifampicin-resistant tuberculosis treatment regimens in South Africa: A retrospective cohort study","volume":"22","author":"Ndjeka","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2025.11.015_bib26","first-page":"1","article-title":"Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis","volume":"62","author":"Mase","year":"2013","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.cmi.2025.11.015_bib27","doi-asserted-by":"crossref","first-page":"E938","DOI":"10.1093\/cid\/ciac528","article-title":"Bedaquiline, delamanid, linezolid, and clofazimine for treatment of pre-extensively drug-resistant tuberculosis","volume":"76","author":"Padmapriyadarsini","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2025.11.015_bib28","doi-asserted-by":"crossref","first-page":"568","DOI":"10.3201\/eid3003.240134","article-title":"Bedaquiline resistance after effective treatment of multidrug-resistant tuberculosis, Namibia","volume":"30","author":"G\u00fcnther","year":"2024","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.cmi.2025.11.015_bib29","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1056\/NEJMe2214707","article-title":"Two steps forward, one step back","volume":"387","author":"Diacon","year":"2022","journal-title":"N Engl J Med"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X25005701?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X25005701?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T22:21:43Z","timestamp":1785363703000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X25005701"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S1198743X25005701"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2025.11.015","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A 6- to 9-months oral regimen for rifampicin-resistant tuberculosis: a randomized open-label noninferiority trial in China","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2025.11.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases.","name":"copyright","label":"Copyright"}]}}